PE20240123A1 - Mutante de il-2 y aplicacion de este - Google Patents
Mutante de il-2 y aplicacion de esteInfo
- Publication number
- PE20240123A1 PE20240123A1 PE2023000835A PE2023000835A PE20240123A1 PE 20240123 A1 PE20240123 A1 PE 20240123A1 PE 2023000835 A PE2023000835 A PE 2023000835A PE 2023000835 A PE2023000835 A PE 2023000835A PE 20240123 A1 PE20240123 A1 PE 20240123A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- fusion protein
- mutant
- polypeptide
- refers
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title abstract 3
- 150000001413 amino acids Chemical group 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102220491264 ADP-ribosylation factor 6_Y31V_mutation Human genes 0.000 abstract 1
- 102220638985 Beta-enolase_H16E_mutation Human genes 0.000 abstract 1
- 102220625993 HMG box transcription factor BBX_D20A_mutation Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 102220098003 rs876661384 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA PROTEINA DE FUSION QUE COMPRENDE: A) UN PRIMER POLIPEPTIDO QUE ES EL MUTANTE DE IL-2 QUE TIENE UNA SECUENCIA DE AMINOACIDOS COMO SE MUESTRA EN UNA CUALQUIERA DE LAS SEQ ID NO: 2, 22, 29, 32 O 37, QUE COMPRENDEN MUTACIONES EN Y31V, A73L, H79Q, V91R, D20A O H16E; Y B) UN SEGUNDO POLIPEPTIDO QUE ES i) UN Fc DE IgG1 HUMANA QUE TIENE UNA SECUENCIA DE AMINOACIDOS COMO SE MUESTRA EN LA SEQ ID NO: 11, ii) UNA MOLECULA DE UNION AL ANTIGENO TUMORAL, O iii) UNA SUBUNIDAD ALFA DEL RECEPTOR DE IL-2. DICHA PROTEINA DE FUSION COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 13, 40, 47, 50 O 55. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHA PROTEINA DE FUSION SIENDO UTIL EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNITARIAS, PROLIFERATIVAS O UNA INFECCION VIRICA.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010918842 | 2020-09-04 | ||
| CN202110932286 | 2021-08-13 | ||
| PCT/CN2021/116463 WO2022048640A1 (zh) | 2020-09-04 | 2021-09-03 | Il-2突变体及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240123A1 true PE20240123A1 (es) | 2024-01-22 |
Family
ID=80490673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000835A PE20240123A1 (es) | 2020-09-04 | 2021-09-03 | Mutante de il-2 y aplicacion de este |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20230265148A1 (es) |
| EP (1) | EP4209503A1 (es) |
| JP (1) | JP2023540761A (es) |
| KR (1) | KR20230061490A (es) |
| CN (1) | CN116323653A (es) |
| BR (1) | BR112023004040A2 (es) |
| CA (1) | CA3191260A1 (es) |
| CL (1) | CL2023000631A1 (es) |
| IL (1) | IL301027A (es) |
| MX (1) | MX2023002648A (es) |
| PE (1) | PE20240123A1 (es) |
| TW (1) | TW202214677A (es) |
| WO (1) | WO2022048640A1 (es) |
| ZA (1) | ZA202304098B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023165553A1 (zh) * | 2022-03-03 | 2023-09-07 | 海南先声药业有限公司 | IL2突变体-抗体Fc嵌段融合蛋白的药物组合物及其应用 |
| US20240076343A1 (en) * | 2022-06-16 | 2024-03-07 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
| WO2023241653A1 (zh) * | 2022-06-17 | 2023-12-21 | 舒泰神（北京）生物制药股份有限公司 | 白介素-2(il-2)突变体及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23734A1 (es) * | 2009-11-27 | 2011-11-15 | Centro Inmunologia Molecular | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
| CN104231068A (zh) * | 2014-01-27 | 2014-12-24 | 苏州发士达生物科技有限公司 | 人白细胞介素ii突变体及其应用 |
| CN113166220A (zh) * | 2018-03-09 | 2021-07-23 | 奥美药业有限公司 | 创新细胞因子前药 |
-
2021
- 2021-09-03 TW TW110132852A patent/TW202214677A/zh unknown
- 2021-09-03 KR KR1020237011285A patent/KR20230061490A/ko unknown
- 2021-09-03 US US18/024,151 patent/US20230265148A1/en active Pending
- 2021-09-03 BR BR112023004040A patent/BR112023004040A2/pt unknown
- 2021-09-03 IL IL301027A patent/IL301027A/en unknown
- 2021-09-03 MX MX2023002648A patent/MX2023002648A/es unknown
- 2021-09-03 PE PE2023000835A patent/PE20240123A1/es unknown
- 2021-09-03 WO PCT/CN2021/116463 patent/WO2022048640A1/zh active Application Filing
- 2021-09-03 JP JP2023515158A patent/JP2023540761A/ja active Pending
- 2021-09-03 CA CA3191260A patent/CA3191260A1/en active Pending
- 2021-09-03 EP EP21863702.3A patent/EP4209503A1/en active Pending
- 2021-09-03 CN CN202180054574.5A patent/CN116323653A/zh active Pending
-
2023
- 2023-03-03 CL CL2023000631A patent/CL2023000631A1/es unknown
- 2023-04-03 ZA ZA2023/04098A patent/ZA202304098B/en unknown
- 2023-12-20 US US18/390,606 patent/US20240209051A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202214677A (zh) | 2022-04-16 |
| CA3191260A1 (en) | 2022-03-10 |
| KR20230061490A (ko) | 2023-05-08 |
| IL301027A (en) | 2023-05-01 |
| MX2023002648A (es) | 2023-04-05 |
| JP2023540761A (ja) | 2023-09-26 |
| WO2022048640A1 (zh) | 2022-03-10 |
| US20240209051A1 (en) | 2024-06-27 |
| ZA202304098B (en) | 2023-09-27 |
| BR112023004040A2 (pt) | 2023-04-04 |
| AU2021338393A1 (en) | 2023-05-11 |
| US20230265148A1 (en) | 2023-08-24 |
| EP4209503A1 (en) | 2023-07-12 |
| CL2023000631A1 (es) | 2023-10-13 |
| CN116323653A (zh) | 2023-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240123A1 (es) | Mutante de il-2 y aplicacion de este | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| PE20220283A1 (es) | Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un medicamento | |
| FI3256579T3 (fi) | Kysteiiniproteaasi | |
| PE20230849A1 (es) | PROTEINAS DE FUSION INTERLEUCINA-2-Fc Y METODOS DE USO | |
| EA201991099A1 (ru) | Антитела против cd73 и их применение | |
| HUP0303171A2 (hu) | Csökkentett immunogenitású mesterséges fehérjék | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| RU2021132097A (ru) | Белки rsv f в предшествующей слиянию конформации и их применение | |
| PE20171336A1 (es) | Anticuerpos contra tau y sus usos | |
| AR119080A1 (es) | Proteínas multiespecíficas | |
| MX2020010806A (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| RU2018141360A (ru) | Contorsbody - одноцепочечный связывающий мишень агент | |
| JP2015504052A5 (es) | ||
| RU2014131605A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| EA202092458A1 (ru) | Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения | |
| ES2828086T3 (es) | Confórmeros abiertos de HLA-B57 | |
| PE20191662A1 (es) | Anticuerpos anti-il-5 | |
| ES2949372T3 (es) | Confórmeros abiertos del CMH de clase Ia | |
| RU2010141916A (ru) | Растворимый мутант рецептора фактора некроза опухоли | |
| BR112022005426A2 (pt) | Polipeptídeos de fusão dap10/dap12 |